CSPC INNOVATION PHARMACEUTICAL CO.,LTD
Commitment to healthy life, faith in goodness
CSPC Innovation Pharmaceutical Co., Ltd. is a subsidiary of CSPC Pharmaceutical Group, a constituent stock of the Hang Seng Index in Hong Kong. It has developed into an innovative company integrating biopharmaceuticals, active pharmaceutical ingredients (APIs), and functional foods. Upholding the corporate philosophy of “Commitment to Healthy Life, Faith to Goodness”, CSPC Innovation insists on leading product development through technological innovation, strictly adheres to product quality with a benevolent mindset, and advances courageously in promoting public nutritional health and contributing to the building of a healthy China.-
-
3Three major product segments
-
-
-
-
470 +Over 470 patent applications
-
-
-
-
2300 +More than 2,300 employees
-
-
-
-
70Marketing in nearly 70 countries or regions
-
-
-
-
22 major innovative drug R&D platforms
-
-
-
-
1515 pipelines under development
-
-
Company News
-
-
-
2026/ 05/11
2026 AACR: SYS6010 Nasopharyngeal Carcinoma Research Results Released by CSPC Innovation
From April 17 to 22, the 117th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA.
-
-
-
-
2026/ 04/28
Five innovative drug research achievements of CSPC Innovation have been selected for the
From May 29 to June 2, 2026, the annual meeting of the American Society of Clinical Oncology (ASCO) will be held in Chicago, USA. At this year’s ASCO conference, CSPC Innovation will present five latest clinical trial progressions of four pipeline products.
-
-
-
-
2025/ 11/18
CSPC Innovative Presents Omalizumab for Injection at 2025 National Congress of Aesthetic Dermatology
From November 6 to 9, the "20th Annual Meeting of the Dermatologists Branch of the Chinese Medical Doctor Association & National Congress of Aesthetic Dermatology" (CDA for short), hosted by the Chinese Medical Doctor Association and the Dermatologists Branch of the Chinese Medical Doctor Association, was grandly held at the Chongqing Science Hall. A large number of experts and scholars in the field of dermatology from across the country gathered at the event.
-
Product Overview
-
-
Biopharmaceuticals
-
-
Functional ingredients
-
-
Nutritional products
-
-
Biopharmaceuticals
The Company focused on cutting-edge biopharmaceutical areas such as antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with more than 20 projects currently under development. It has launched China's first mRNA vaccine, Duentai, the Class 1 new biological drug Enlonstobart injection, and Omalizumab for injection.
-
-
Functional ingredients
The products mainly include caffeine, acarbose, anhydrous glucose, etc. The caffeine products lead the world in production scale, and the production scale of acarbose raw materials ranks among the top in China, achieving industrialized production of acarbose products. It is currently one of the few domestic companies with an official drug approval number for acarbose APIs.
-
-
Nutritional products
The company has established a dietary nutrition product matrix with 8 major categories: Vitamin C, B vitamins, glucosamine, calcium, protein powder, coenzyme Q10, lutein, and melatonin, covering functional needs such as "immune support, bone health, improved sleep, digestive care, and antioxidation," as well as chronic disease health needs like "regulating the three highs" (blood pressure, blood sugar, and blood lipids).
